ReviewFrontiers in pharmacology2019
Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Managing metabolic syndrome in bipolar disorder: multidisciplinary monitoring and treatment strategies.Frontiers in psychiatry · 2026Review
- Associations of ANKK1 (rs1800497) polymorphism with glucose and lipid metabolism in patients with schizophrenia treated with olanzapine: a retrospective study.Annals of general psychiatry · 2025Article
- Combination of UGT1A1 polymorphism and baseline plasma bilirubin levels in predicting the risk of antipsychotic-induced dyslipidemia in schizophrenia patients.Schizophrenia (Heidelberg, Germany) · 2024Article
- Investigating the Effect of Adherence to Antipsychotic Therapy on the Length of Stay and Number of Hospitalizations in Patients with Schizophrenia - A Descriptive Analysis.Patient preference and adherence · 2023Article
- Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome.Journal of personalized medicine · 2022Article
- The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia.Genes · 2022Article
- Article
- Associations of theJournal of personalized medicine · 2021Article
- Review: Influence of the CYP450 Genetic Variation on the Treatment of Psychotic Disorders.Journal of clinical medicine · 2021Review
- Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case-control study.Scientific reports · 2021Article
- Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.Journal of experimental & clinical cancer research : CR · 2021Article
- Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a NewFrontiers in psychiatry · 2021Article
- On the Role of Central Type-1 Cannabinoid Receptor Gene Regulation in Food Intake and Eating Behaviors.International journal of molecular sciences · 2021Review
- The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.Frontiers in psychiatry · 2021Review
- Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy.Journal of personalized medicine · 2020Article
- The Role of Adiponectin in the Pathogenesis of Metabolic Disturbances in Patients With Schizophrenia.Frontiers in psychiatry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic side effects such as weight gain and disturbed lipid metabolism are often observed in the treatment of atypical antipsychotic drugs (AAPDs), which contribute to an excessive prevalence of metabolic syndrome among schizophrenic patients. Great individual differences are observed but the underlying mechanisms are still uncertain. Research on pharmacogenomics indicates that gene polymorphisms involved in the pathways controlling food intake and lipid metabolism may play a significant role. In this review, relevant genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.